Thalidomide-O-amido-C8-NH2

Background Introduction

Thalidomide-O-amido-C8-NH2 is a specialized bifunctional molecule employed as a building block in the synthesis of PROTACs (Proteolysis Targeting Chimeras) and molecular glues. Featuring a thalidomide-derived E3 ligase ligand connected via an amide bond to a C8 alkyl linker terminated with an amine group, this conjugate is designed for high compatibility with various reactive groups during PROTAC assembly. Its tailored structure enables researchers to efficiently create compounds that harness targeted protein degradation, a powerful therapeutic strategy being explored in drug discovery.

Mechanism

The mechanism of Thalidomide-O-amido-C8-NH2 centers on targeted protein ubiquitination and degradation via the ubiquitin-proteasome system. The thalidomide moiety specifically binds to the cereblon (CRBN) E3 ubiquitin ligase, an essential component of the CRL4^CRBN complex. The terminal amine group on the C8 linker allows for conjugation with other active molecules, typically a ligand for a target protein. When incorporated into a PROTAC molecule, the construct simultaneously binds the target protein and cereblon E3 ligase, promoting proximity-induced ubiquitination of the target protein, which is subsequently recognized and degraded by the proteasome.

Applications

Thalidomide-O-amido-C8-NH2 is primarily used in the construction of cereblon-based PROTACs for targeted protein degradation. Its robust, adaptable linker enables efficient synthesis of bifunctional molecules tailored to degrade disease-relevant proteins implicated in cancer, neurodegenerative disorders, and autoimmune diseases. Additionally, this conjugate finds value in chemical biology research, enabling drug target validation and mechanistic studies of protein function. It supports the rapid prototyping and optimization of next-generation therapeutics and research tools designed for selective protein knockdown and functional modulation in living cells.

• Flexible C8 linker improves spatial orientation for efficient CRBN E3 ligase recruitment in PROTAC design.
• Amine-terminated structure enables straightforward conjugation to diverse warheads, streamlining PROTAC synthesis.

The E3 Ligase Ligand-Linker Conjugate, Thalidomide-O-amido-C8-NH2, plays a crucial role in PROTAC technology by facilitating the targeted degradation of proteins. It combines a thalidomide-based ligand with a versatile linker to enable the precise recruitment of E3 ligases, enhancing the specificity and efficacy of protein degradation. The following provides a detailed description of this molecule.

Linker: The linker in this molecule is an amido-C8 chain, providing moderate length and flexibility, which is essential for effective spatial orientation. Its non-cleavable nature ensures stability, maintaining the integrity of the conjugate during the degradation process.

Ligand: The ligand component is thalidomide-based, a well-characterized cereblon binder. Its structural characteristics include an imide moiety, which is critical for engaging with the E3 ligase, enabling targeted protein ubiquitination and subsequent degradation.

Reactive Site: The reactive site is an amine group at the terminus of the C8 linker, designed to couple efficiently with the target protein ligand. Recommended reaction types include amide bond formation or reductive amination, facilitating robust and stable conjugation.

Recommended Target Protein Ligand: The molecule is compatible with electrophilic warheads, such as acrylamides or chloroacetamides, which are advantageous due to their ability to form covalent bonds with cysteine residues on target proteins. This compatibility enhances the selectivity and potency of the PROTAC, making it suitable for applications in studying protein function and validating therapeutic targets in cellular models.